Literature DB >> 11320356

Infarct artery reocclusion after primary angioplasty, stent placement, and thrombolytic therapy for acute myocardial infarction.

S H Wilson1, M R Bell, C S Rihal, K R Bailey, D R Holmes, P B Berger.   

Abstract

BACKGROUND: The benefits of thrombolytic therapy for acute myocardial infarction (AMI) are limited by reocclusion of the infarct-related artery, which occurs in 25% to 30% of patients after successful reperfusion. The frequency of reocclusion after balloon angioplasty and stenting in this setting is less well documented. The aim of this study was to analyze the frequency and timing of reocclusion after percutaneous transluminal coronary angioplasty (PTCA) and stent placement during AMI from all available studies compared with previously published reocclusion rates after thrombolysis. METHODS AND
RESULTS: The previously published thrombolysis data included 4231 patients in 19 studies with > or = 75 patients. Only PTCA studies with > or = 50 patients and stent studies with > or = 30 patients, in which routine angiographic follow-up was obtained in > or = 60% of patients, were included. Ten PTCA studies with a total of 1943 patients were analyzed, with follow-up angiography in 1391 (72%). Reocclusion rates ranged from 5% to 16.7%. The stent studies included 698 patients from 7 studies, with follow-up angiography in 92%. Reocclusion rates ranged from 0% to 6%. With the use of logistic regression analysis with allowance for overdispersion, there was a significantly lower rate of reocclusion after PTCA (odds ratio, 0.38; confidence interval, 0.24 to 0.57; P <.0001) and stent placement (odds ratio, 0.11; confidence interval, 0.05 to 0.22; P <.0001) compared with thrombolysis. Reocclusion after stent placement was lower than after PTCA (odds ratio, 0.28; confidence interval, 0.13 to 0.6; P <.0001).
CONCLUSIONS: Reocclusion after PTCA and stent placement during AMI is less frequent than after thrombolysis. This may contribute to the superior outcome of patients treated with PTCA and stent placement in this setting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320356     DOI: 10.1067/mhj.2001.114971

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction.

Authors:  Emily C O'Brien; Kathryn M Rose; Chirayath M Suchindran; Til Stürmer; Patricia P Chang; Lloyd Chambless; Cameron S Guild; Wayne D Rosamond
Journal:  Heart       Date:  2013-03-02       Impact factor: 5.994

2.  Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells.

Authors:  H Kothari; G Kaur; S Sahoo; S Idell; L V M Rao; U Pendurthi
Journal:  J Thromb Haemost       Date:  2008-11-03       Impact factor: 5.824

3.  Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.

Authors:  You fu Li; Frederick A Spencer; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 4.  A quantitative estimate of bare-metal stenting compared with balloon angioplasty in patients with acute myocardial infarction: angiographic measures in relation to clinical outcome.

Authors:  Tone Svilaas; Iwan C C van der Horst; Felix Zijlstra
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

5.  Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia.

Authors:  C Lupu; O Herlea; H Tang; R H Lijnen; F Lupu
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.